Acadia Pharmaceuticals Inc. ( ACAD) - Stock Earnings
ACAD Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 4, 2026, midnight | — / — | — | — / — | — |
ACAD Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | 273.6 million USD | 284.0 million USD |
| 2026Q1 | 3.6 million USD | 268.1 million USD |
| 2026Q2 | 31.5 million USD | 308.0 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
ACAD Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -61.3 million USD | 726.4 million USD |
| 2024 | 226.5 million USD | 957.8 million USD |
| 2025 | 391.0 million USD | 1.1 billion USD |
| 2026 Est. | — | — |
ACAD
Price: $19.71
Earnings Per Share: 2.24 USD
P/E Ratio: 13.12
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.4 million
Ebitda: -65.6 millionMarket Capitalization: 3.4 billion